Skip to NavigationSkip to content

Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million

Published on 20/12/18 at 04:48pm

German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a deal worth $175 million.

Intrexon will hand over $150 million in stock and a $25 million convertible note. The company will in turn receive a $25 million cash investment. Thus Merck will maintain an investment in the next generation of CAR-T therapies.

The new deal comes three years after Merck forged a $941 million deal with Intrexon in 2015. Merck has characterised the move as an attempt to streamline their R&D processes.

However the firm has failed to make a lasting impression when it comes to CAR-T therapies having been overtaken by Swiss firm Novartis and Gilead subsidiary Kite. Shares in Intrexon were up 8% premarket but down overall.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches